Carloni Riccardo, Rizzo Alessandro, Ricci Angela Dalia, Frega Giorgio, Federico Alessandro Di, Palloni Andrea, Marco Mariacristina Di, Gadaleta-Caldarola Gennaro, Brandi Giovanni
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy.
Medical Oncology Unit, 'Mons. R. Dimiccoli' Hospital, Barletta (BT), Azienda Sanitaria Locale Barletta, 76121, Italy.
Future Oncol. 2022 Mar;18(8):1023-1034. doi: 10.2217/fon-2021-0905. Epub 2022 Feb 3.
Hepatocellular carcinoma (HCC) represents the fourth most common cause of cancer-related death. Surgery, local ablative therapies and liver transplantation are the only potentially curative strategies, but the majority of patients present with advanced disease at diagnosis or develop recurrence after surgery. In recent years, immunotherapy for HCC has received growing interest, and one of the most promising strategies is the association of two immune checkpoint inhibitors (ICIs), which has already demonstrated its potential in other solid tumors such as melanoma and renal cell carcinoma. Herein, we discuss the role and the biologic rationale of dual immune checkpoint blockade in HCC patients, focusing on the two ICI combinations: nivolumab plus ipilimumab and durvalumab plus tremelimumab.
肝细胞癌（HCC）是癌症相关死亡的第四大常见原因。手术、局部消融治疗和肝移植是仅有的潜在治愈性策略，但大多数患者在诊断时已处于晚期疾病状态，或术后出现复发。近年来，HCC的免疫治疗越来越受到关注，最有前景的策略之一是联合使用两种免疫检查点抑制剂（ICI），这一联合疗法已在黑色素瘤和肾细胞癌等其他实体瘤中展现出潜力。在此，我们讨论双重免疫检查点阻断在HCC患者中的作用及生物学原理，重点关注两种ICI联合方案：纳武利尤单抗联合伊匹木单抗以及度伐利尤单抗联合曲美木单抗。
